Answers are grounded in this paper and cite their sources.
A decade on, while the basic principles discussed in the first review of the patent landscape of antibody–drug conjugates still apply, the ADC landscape has dramatically evolved and diversified.
No takes yet. Share an insight, caveat, or question.
Ulrich Storz (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: